Recall that Lilly management had a 'mandate' to eliminate 5,500 positions by end of 2011 (starting in fall of 2009). From the last update I saw mid-year, they said they were 'on pace'. It is about a 27 month period from Oct 2009 - Dec 2011, so 5500/27 = 204 positions per month on average. Assuming they are still 'on pace' with the 50-60 weekly cuts we have been continually informed of on this thread, that leaves about only 300 more cuts by year end to meet the quota.
HOWEVER, no-one should believe that additional cuts are not coming soon. With the loss of Bydureon potential sales (probably a dud anyway), the likely poor performance of Tradjenta, and a continuing sham of a late-stage pipeline, thousands more cuts should be expected by anyone without their head in the sand.